TargetMol

Sofosbuvir impurity G

Product Code:
 
TAR-T12962
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T12962-1mg1mg£1,155.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T12962-5mg5mg£2,874.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T12962-1mL1 mL * 10 mM (in DMSO)£3,259.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T12962-10mg10mg£3,838.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T12962-25mg25mg£5,589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T12962-50mg50mg£7,669.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Sofosbuvir impurity G is both a diastereomer of Sofosbuvir and an impurity of Sofosbuvir which is an inhibitor of HCV RNA replication.
CAS:
1337482-15-1
Formula:
C22H29FN3O9P
Molecular Weight:
529.458
Pathway:
Microbiology/Virology; Proteases/Proteasome
Purity:
0.9804
SMILES:
CC(C)OC(=O)[C@H](C)N[P@](=O)(O[C@@H]1[C@@H](CO)O[C@@H](n2ccc(=O)[nH]c2=O)[C@]1(C)F)Oc1ccccc1
Target:
HCV Protease

References

1. Baker MM, Hammad SF, Belal TS. Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies. Drug Dev Ind Pharm. 2019 Jul;45(7):1111-1119.